syringes for glp 1 GLP-1 drugs effective weight loss, but more independent studies needed Compounded GLP-1 Medications: Risks and

Nature 2020;577:4326.PubMed 47

While the exact mechanism remains unclear, this reduction could be tied to weight loss, visceral fat reduction, improved glucose control, or potentially an independent anti-inflammatory effect

Novo Nordisk presented the phase 3 monotherapy results in September 2025 and submitted an NDA for CagriSema to the FDA on 18 December 2025, based on REDEFINE 1 and REDEFINE 2

Kristi L

This supports healthy weight management and helps burn fat more effectively, making it a helpful remedy in maintaining an active lifestyle

doi: 10.1042/bj2650621 44 BurdickNCBernhardBCCarrollJARathmannRJJohnsonBJ